| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F Jenck, M Bös, J Wichmann, H Stadler, J R Martin, J L Morea. The role of 5-HT2C receptors in affective disorders. Expert opinion on investigational drugs. vol 7. issue 10. 2005-07-26. PMID:15991903. |
5-ht(2c) receptors are predominantly localised in the brain and their dysregulation may contribute to particular symptoms of anxiety and depression. |
2005-07-26 |
2023-08-12 |
human |
| D T Won. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert opinion on investigational drugs. vol 7. issue 10. 2005-07-26. PMID:15991911. |
duloxetine offers an opportunity to utilise combined central 5-ht and ne neuronal pathways to improve the treatment of patients with major depression. |
2005-07-26 |
2023-08-12 |
mouse |
| J Fennell, M Hussai. Serotonin syndrome:case report and current concepts. Irish medical journal. vol 98. issue 5. 2005-07-26. PMID:16010782. |
selective serotonin reuptake inhibitors (ssri's) are increasingly being used as the first line therapeutic agent for the depression. |
2005-07-26 |
2023-08-12 |
Not clear |
| M-P Pancrazi, P Metai. [Treatment of the psychological and behavioural disorders of Alzheimer's disease]. Presse medicale (Paris, France : 1983). vol 34. issue 9. 2005-07-20. PMID:15988346. |
some selective serotonin reuptake inhibitors agents may be useful not only in depression but also anxiety, emotional disturbances, irritability and compulsiveness. |
2005-07-20 |
2023-08-12 |
Not clear |
| Michael E Thase, Pierre V Tran, Curtis Wiltse, Beth A Pangallo, Craig Mallinckrodt, Michael J Detk. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of clinical psychopharmacology. vol 25. issue 2. 2005-07-15. PMID:15738744. |
this analysis assessed the effects of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on indices of cardiovascular safety, including heart rate, blood pressure (bp), and electrocardiograms (ecgs), in a large group of clinical trial patients with depression. |
2005-07-15 |
2023-08-12 |
Not clear |
| Patrick Osei-Owusu, Amy James, James Crane, Karie E Scrogi. 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. The Journal of pharmacology and experimental therapeutics. vol 313. issue 3. 2005-07-14. PMID:15743927. |
neuroendocrine responses to administration of serotonin releasing agents or 5-hydroxytryptamine (5-ht) 1a receptor agonists have been used as an index of serotonin receptor function in patients with depression and other mood disorders. |
2005-07-14 |
2023-08-12 |
rat |
| Paul Willner, Anthony S Hale, Spilios Argyropoulo. Dopaminergic mechanism of antidepressant action in depressed patients. Journal of affective disorders. vol 86. issue 1. 2005-07-12. PMID:15820269. |
the participants were patients diagnosed with major depressive disorder (n = 8) who had been treated successfully (hamilton depression scale < 10) with selective serotonin uptake inhibitors (fluoxetine, citalopram or paroxetine); and age-matched, non-depressed, untreated volunteers (n = 10). |
2005-07-12 |
2023-08-12 |
human |
| C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. |
differential camp levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. |
2005-07-11 |
2023-08-12 |
human |
| C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. |
in lymphocytes from major depression patients, serotonin and 8-hydroxy-(dipropylamino)tetralin significantly increased camp levels, which was slightly reduced by way-100,135. |
2005-07-11 |
2023-08-12 |
human |
| C Mizrahi, A Stojanovic, M Urbina, I Carreira, L Lim. Differential cAMP levels and serotonin effects in blood peripheral mononuclear cells and lymphocytes from major depression patients. International immunopharmacology. vol 4. issue 8. 2005-07-11. PMID:15270025. |
the present report indicates: (1) differential responses of immune cells from control individuals and depressed patients, with lower apparent adenylate cyclase activity in patient's cells; (2) variation in the population of cells, with responses to serotonergic agonists being lower in mononuclear cells and higher in lymphocytes from major depression patients; (3) increases of camp levels by serotonin and 5ht1a agonist in the patient's cells; and (4) evidence of impairment in serotonergic transduction systems in immune cells during depression. |
2005-07-11 |
2023-08-12 |
human |
| Ph Quintin, P Thoma. [Efficacy of atypical antipsychotics in depressive syndromes]. L'Encephale. vol 30. issue 6. 2005-07-08. PMID:15738862. |
moreover, most of the atypical antipsychotics have a large action spectrum, beyond the only dopamine receptors: their effects on the serotonin receptors--particularly the 5-ht2a and 5-ht2c receptors--suggest that their association to ssri could be a promising treatment for depression. |
2005-07-08 |
2023-08-12 |
Not clear |
| Philip J Cowen, Alan D Ogilvie, Joubert Gam. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Current medical research and opinion. vol 21. issue 3. 2005-07-05. PMID:15811202. |
recently, dualacting antidepressants, which block both serotonin (5-ht) and noradrenaline (na) reuptake, have been developed with the hope of improving depression treatment outcomes. |
2005-07-05 |
2023-08-12 |
Not clear |
| Pavel Hamet, Johanne Trembla. Genetics and genomics of depression. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877306. |
gene-environment interaction has been recognized for a long time in the pathophysiology of depression, and its best biological substratum at present is represented by the serotonin transporter (5-htt) gene, where several copies of its short allele culminate in depression and suicide in response to lifelong stress events. |
2005-07-05 |
2023-08-12 |
mouse |
| Richard J Wurtma. Genes, stress, and depression. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877307. |
the specific genetic locus causing serotonin uptake to be lower in some patients with major depression involves a polymorphic region (5-httlpr) in the promoter region of the gene for the uptake protein. |
2005-07-05 |
2023-08-12 |
human |
| Madhu Kali. Neurobiological basis of depression: an update. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877309. |
new neurobiological concepts have emerged, as they relate to these advances in mental health research such as the serotonin transporter receptor, a genetic variant of which doubles the risk of depression. |
2005-07-05 |
2023-08-12 |
Not clear |
| Madhu Kali. Neurobiological basis of depression: an update. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877309. |
several brain neurotransmitters systems: glutamate, gamma -aminobutyric acid, serotonin, norepinephrine, and dopamine have been implicated in depression and mania. |
2005-07-05 |
2023-08-12 |
Not clear |
| Gérard E Plant. Depression and cardiovascular disease: a reciprocal relationship. Metabolism: clinical and experimental. vol 54. issue 5 Suppl 1. 2005-07-05. PMID:15877313. |
since hans selye first described the neuroendocrine cascade generated by experimentally induced stress half a century ago, phenomena such as the axonal release of neurotransmitters (including serotonin), accumulation of metabolites such as homocysteine, platelet-activating factor, and nitric oxide also have been implicated in the pathogenesis of depression. |
2005-07-05 |
2023-08-12 |
Not clear |
| Grazyna Jasienska, Anna Ziomkiewicz, Maciej Górkiewicz, Andrzej Paja. Body mass, depressive symptoms and menopausal status: an examination of the "Jolly Fat" hypothesis. Women's health issues : official publication of the Jacobs Institute of Women's Health. vol 15. issue 3. 2005-07-05. PMID:15894200. |
estrogens are linked with depression due to their ability to alter the function of the serotonin neural systems. |
2005-07-05 |
2023-08-12 |
Not clear |
| Moonkyu Kang, Kwang-Ho Pyun, Choon-Gon Jang, Hyuntaek Kim, Hyunsu Bae, Insop Shi. Nelumbinis Semen reverses a decrease in hippocampal 5-HT release induced by chronic mild stress in rats. The Journal of pharmacy and pharmacology. vol 57. issue 5. 2005-06-28. PMID:15901354. |
recently, several lines of evidence have suggested that a very important evoking factor in depression may be a serotonin deficit in the hippocampus. |
2005-06-28 |
2023-08-12 |
rat |
| Moonkyu Kang, Kwang-Ho Pyun, Choon-Gon Jang, Hyuntaek Kim, Hyunsu Bae, Insop Shi. Nelumbinis Semen reverses a decrease in hippocampal 5-HT release induced by chronic mild stress in rats. The Journal of pharmacy and pharmacology. vol 57. issue 5. 2005-06-28. PMID:15901354. |
these results suggest that ns increases the serotonin levels normally decreased in depression, resulting in an enhancement of central serotonergic transmission and possible therapeutic action in depression. |
2005-06-28 |
2023-08-12 |
rat |